Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.33 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | BCL2A1 | Q16548 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL151254 | 0.81 | MAPT (0.40) | L3MBTL1KDM4EKMT2AMEN1POLB | |
| SCHEMBL149845 | 0.79 | ALDH1A1 (0.38) | KDM4EGAAKMT2AMEN1POLB | |
| SCHEMBL2124718 | 0.79 | DPP4 (0.46) | L3MBTL1KDM4EGAADPP4KMT2A | |
| SCHEMBL2126214 | 0.79 | LMNA (0.41) | KDM4EGAAMRGPRX4TSHRMAPT | |
| SCHEMBL14252745 | 0.75 | SMN1; SMN2 (0.40) | L3MBTL1KDM4EPOLBTSHRMAPT | |
| SCHEMBL28138436 | 0.74 | SMN1; SMN2 (0.40) | L3MBTL1KDM4EKMT2APOLBTSHR | |
| SCHEMBL28166903 | 0.73 | TBXAS1 (0.37) | PTGS2 | |
| SCHEMBL2126764 | 0.73 | EGFR (0.43) | KDM4EGAAKMT2AMEN1MAPT | |
| SCHEMBL153427 | 0.72 | MAPT (0.39) | L3MBTL1KDM4EGAAKMT2AMEN1 | |
| SCHEMBL31058820 | 0.72 | RAB9A (0.49) | L3MBTL1KDM4EMRGPRX4KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120289520-A1 | CHEMICAL COMPOUNDS 785 | ASTRAZENECA AB (SE) | 2012-11-15 | — | — | US | disclosed |
| US-20120289520-A1 | CHEMICAL COMPOUNDS 785 | ASTRAZENECA AB (SE) | 2012-11-15 | — | — | US | disclosed |
| US-20120289520-A1 | CHEMICAL COMPOUNDS 785 | ASTRAZENECA AB (SE) | 2012-11-15 | — | — | US | disclosed |
| US-8188092-B2 | Substituted pyrazines as DGAT-1 inhibitors | ASTRAZENECA AB (SE) | 2012-05-29 | — | — | US | disclosed |
| US-8188092-B2 | Substituted pyrazines as DGAT-1 inhibitors | ASTRAZENECA AB (SE) | 2012-05-29 | — | — | US | disclosed |
| US-8188092-B2 | Substituted pyrazines as DGAT-1 inhibitors | ASTRAZENECA AB (SE) | 2012-05-29 | — | — | US | disclosed |
| EP-2443096-A1 | PYRAZINE CARBOXAMIDES AS INHIBITORS OF DGAT1 | AstraZeneca AB (SE) | 2012-04-25 | — | — | EP | disclosed |
| US-20100324068-A1 | CHEMICAL COMPOUNDS 785 | ASTRAZENECA AB (SE) | 2010-12-23 | — | — | US | disclosed |
| US-20100324068-A1 | CHEMICAL COMPOUNDS 785 | ASTRAZENECA AB (SE) | 2010-12-23 | — | — | US | disclosed |
| US-20100324068-A1 | CHEMICAL COMPOUNDS 785 | ASTRAZENECA AB (SE) | 2010-12-23 | — | — | US | disclosed |
| WO-2010146395-A1 | PYRAZINE CARBOXAMIDES AS INHIBITORS OF DGAT1 | ASTRAZENECA AB (SE) | 2010-12-23 | — | — | WO | disclosed |
| WO-2010146395-A1 | PYRAZINE CARBOXAMIDES AS INHIBITORS OF DGAT1 | ASTRAZENECA AB (SE) | 2010-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324068-A1 | CHEMICAL COMPOUNDS 785 | GPBAR1, DGAT1, GPR119 | L3MBTL1 1548/4885KDM4E 2095/4885GAA 200/4885 |
| US-20120289520-A1 | CHEMICAL COMPOUNDS 785 | DGAT1, DGAT2, SLC5A1 | L3MBTL1 3405/4885KDM4E 2115/4885GAA 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.